Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Pain. 2022 Nov 14;164(6):1340–1354. doi: 10.1097/j.pain.0000000000002824

Figure 8. Intrathecal 3-oxa-PD1 treatment inhibits persistent itch in mice following DNFB-induced dermatitis and imiquimod-induced psoriasis.

Figure 8.

(A) Protocol of experimental design for the mouse DNFB model. (B) Intrathecal administration of 3-oxa-PD1 (100 ng) reduced the number of scratching. Two-way ANOVA with Bonferroni’s post hoc test. F (1, 60) = 13.68, n=6 mice (vehicle) and n=8 mice (3-oxa-PD1). (C) Protocol of experimental design for the mouse psoriasis model induced by imiquimod (IMQ). (D) Intrathecal administration of 3-oxa-PD1 (100 ng) reduced the number of scratching. Two-way ANOVA with Bonferroni’s post hoc test. F (1, 60) = 13.68, n=6 mice (vehicle) and n=8 mice (3-oxa-PD1). Data are shown as mean ± SEM. *P < 0.05,